Chimerix Inc - Company Profile
Powered by 
All the sales intelligence you need on Chimerix Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chimerix Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chimerix Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chimerix Inc (Chimerix), a subsidiary of Jazz Pharmaceuticals Plc, is a biopharmaceutical company that develops therapies for oncology diseases. The company offers pipeline products such as Dordaviprone ONC201, is a small molecule imipridone, which treats H3 K27M-mutant diffuse glioma; ONC206 for the treatment of central nervous system tumors and non-central nervous system tumors; CMX521 and ONC212. It collaborates with various strategic partners, including CR Pharmaceutical, Emergent, Ohara, Oncoceutics, Pacific Pediatric Neuro-Oncology Consortium, and Readdi. Chimerix is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
Suite 100, 2505 Meridian Parkway, Durham, North Carolina, 27713
Website
www.chimerix.com/
Telephone
1 919 8061074
No of Employees
79
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$212,000
Chimerix Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Dordaviprone ONC201: H3 K27M-Mutant Diffuse Glioma |
| ONC206: Central Nervous System Tumors and Non-Central Nervous System Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In April, the company was acquired by Jazz Pharmaceuticals for US$935 million. |
| 2021 | Acquisitions/Mergers/Takeovers | In January, the company acquired Oncoceutics, Inc., a clinical-stage biotechnology company. |
| 2014 | New Products/Services | In October, the company introduced brincidofovir that has been provided for potential use in patients with Ebola Virus Disease and was approved by FDA. |
Competitor Comparison
| Key Parameters | Chimerix Inc | Aclaris Therapeutics Inc | Callio Therapeutics Inc | Candel Therapeutics Inc | Novartis Gene Therapies |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Durham | Wayne | Seattle | Needham | Bannockburn |
| State/Province | North Carolina | Pennsylvania | Washington | Massachusetts | Illinois |
| No. of Employees | 79 | 69 | - | 55 | - |
| Entity Type | Private | Public | Private | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael T. Andriole | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Michelle LaSpaluto | Chief Financial Officer | Senior Management | 2023 | - |
| Tom Riga | Chief Commercial Officer; Chief Operating Officer | Senior Management | 2023 | - |
| Roy W. Ware, PhD | Chief Manufacturing Officer; Chief Technology Officer | Senior Management | 2017 | - |
| Allen Melemed, MD | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer